Royal Bank of Canada
NMRA icon

Royal Bank of Canada’s Neumora Therapeutics NMRA Stock Holding History

Royal Bank of Canada’s Portfolio NMRA Stock Details NMRA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$2K Sell
1,178
-1,689
-59% -$4.38K ﹤0.01% 6730
2025
Q4 		$5K Buy
2,867
+835
+41% +$1.83K ﹤0.01% 6720
2025
Q3 		$3K Buy
2,032
+920
+83% +$1.49K ﹤0.01% 6813
2025
Q2 		$1K Buy
1,112
+564
+103% +$427 ﹤0.01% 6911
2025
Q1 		$0 Sell
548
-2,051
-79% -$3.51K ﹤0.01% 7098
2024
Q4 		$27K Sell
2,599
-6,736
-72% -$80.7K ﹤0.01% 5983
2024
Q3 		$123K Buy
9,335
+1,376
+17% +$16.1K ﹤0.01% 5191
2024
Q2 		$78K Sell
7,959
-42,775
-84% -$443K ﹤0.01% 5417
2024
Q1 		$698K Buy
50,734
+45,795
+927% +$740K ﹤0.01% 3742
2023
Q4 		$84K Sell
4,939
-15,139
-75% -$186K ﹤0.01% 5721
2023
Q3 		$283K Buy
+20,078
New +$251K ﹤0.01% 4499

Other funds holding NMRA

SL
Siren LLC Greenwich, Connecticut $3.61B AUM 203.3% 1-Year Est. Return
SoftBank Group
SoftBank Group Tokyo, Japan $11.4B AUM 27.91% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
MCMU
MIC Capital Management (UK) London, United Kingdom $352M AUM 0.23% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
WT
Wellcome Trust London, United Kingdom $9.01B AUM 12.05% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
IC
Iconiq Capital San Francisco, California $4.46B AUM 22.86% 1-Year Est. Return
LC
Lunate Capital Al Maryah Island, Abu Dhabi, United Arab Emirates $196M AUM 84.21% 1-Year Est. Return

Royal Bank of Canada's NMRA Position: Q1 2026 in Review

Royal Bank of Canada reduced its Neumora Therapeutics (NMRA) stake by 59% in Q1 2026, selling an estimated $4.38K and leaving 1,178 shares worth $2K. The position accounts for ﹤0.01% of the portfolio, ranked #6730.

Royal Bank of Canada first reported a position in NMRA in Q3 2023 and has held it in 11 quarters since. The position peaked at $698K in Q1 2024. 114 funds tracked by Wall St. Rank hold NMRA as of Q1 2026.

  • Royal Bank of Canada held 1,178 shares of Neumora Therapeutics worth $2K as of Q1 2026.
  • Royal Bank of Canada sold 1,689 Neumora Therapeutics shares in Q1 2026, an estimated $4.38K.
  • Neumora Therapeutics made up ﹤0.01% of Royal Bank of Canada's portfolio in Q1 2026, its #6730 holding.
  • Royal Bank of Canada first reported a position in Neumora Therapeutics in Q3 2023 and has held it in 11 quarters since.
  • Royal Bank of Canada's Neumora Therapeutics position peaked at $698K in Q1 2024.
  • 114 funds tracked by Wall St. Rank held Neumora Therapeutics as of Q1 2026.

Based on Royal Bank of Canada's 13F filing for Q1 2026, filed 15 May 2026.